AlloVir, Inc.

Allovir, Inc. is a clinical-stage cell therapy company specializing in allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for the prevention and treatment of viral-associated diseases. Its lead product, posoleucel, targets various viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. The company also has preclinical and clinical development product candidates for respiratory syncytial virus, influenza, parainfluenza virus, human metapneumovirus, SARS-CoV-2, COVID-19, and hepatitis B. Allovir, Inc. generates revenue through the research, development, and commercialization of its allogeneic VST therapies.

Products

• Posoleucel (allogeneic, off-the-shelf VST therapy)

• ALVR106 (respiratory syncytial virus, influenza, parainfluenza virus, human metapneumovirus)

• ALVR109 (SARS-CoV-2, COVID-19)

• ALVR107 (hepatitis B)

• ALVR108 (preclinical and clinical development product)